RxDoctor Payments Data

Margaret Wong Gribble, MD

Uveitis and Ocular Inflammatory Disease · Atlanta, GANPI 1477723187

Payments from drug & device makers

$342,142in general payments, 2019–2025

Across 683 payments — averaging $500.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$249K
  • Astellas Pharma US Inc$37K
  • AbbVie$21K
  • Mallinckrodt Enterprises LLC$18K
  • Eyepoint US, Inc.$7K
  • Regeneron Healthcare Solutions, Inc.$2K
  • plus $8K from 22 others

What the payments were for

  • Consulting fees$10,4183%
  • Speaking & faculty fees$271,35079%
  • Travel & lodging$40,38512%
  • Food & beverage$19,7616%
  • Education$1880%
  • Gifts$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few uveitis and ocular inflammatory disease providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,952,454
Medicare patients
787
Services billed
40,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin16$1,641,480
Difluprednate185$18,249
Prednisolone Acetate229$13,676
ProlensaBromfenac Sodium35$11,899
RestasisCyclosporine12$11,534
Lotemax SmLoteprednol Etabonate34$9,244
Bromfenac Sodium31$7,315
Ketorolac Tromethamine240$5,901
CombiganBrimonidine Tartrate/Timolol26$5,552
Atropine Sulfate52$3,899
Mycophenolate Mofetil36$2,997
ValacyclovirValacyclovir Hcl29$2,490
Gatifloxacin45$1,855
Moxifloxacin Hcl11$1,261
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$1,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$249,352$1,641,48016 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$163$21,14369 claims
AbbVieRestasis, Combigan$20,864$17,08538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few uveitis and ocular inflammatory disease providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →